2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsQuality of Care in the United States Territories, 1999–2012
Nuti SV, Wang Y, Masoudi FA, Nunez-Smith M, Normand ST, Murugiah K, Rodríguez-Vilá O, Ross JS, Krumholz HM. Quality of Care in the United States Territories, 1999–2012. Medical Care 2017, 55: 886-892. PMID: 28906314, PMCID: PMC6482857, DOI: 10.1097/mlr.0000000000000797.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionHeart failureHospitalization ratesMedicare beneficiariesMortality rateService Medicare beneficiariesQuality of careRecent study periodPneumonia hospitalizationsMyocardial infarctionPatient outcomesMillions of AmericansMedicare feeHealth outcomesPneumoniaService beneficiariesHospital reimbursementUnique beneficiariesHealth equityStudy periodPatient paymentsInpatient paymentsHealth careMortalityCare
2003
Aligning quality and payment for heart failure care: Defining the challenges
Havranek EP, Krumholz HM, Dudley RA, Adams K, Gregory D, Lampert S, Lindenfeld J, Massie BM, Pina I, Restaino S, Rich MW, Konstam MA. Aligning quality and payment for heart failure care: Defining the challenges. Journal Of Cardiac Failure 2003, 9: 251-254. PMID: 13680543, DOI: 10.1054/jcaf.2003.30.Peer-Reviewed Original ResearchMeSH KeywordsDelivery of Health CareHeart FailureHumansInsurance, Health, ReimbursementQuality of Health CareUnited StatesConceptsHigh-quality careQuality careHeart Failure SocietyHeart failure careHeart failure patientsQuality of careFailure patientsHeart failureReadmission ratesRecent roundtable discussionDisease severityInterests of patientsCarePatientsHospitalReimbursement systemReimbursement schemesEmpty bedsPhysicians
1997
Differences in physician compensation for cardiovascular services by age, sex, and race.
Krumholz HM, Fendrick AM, Williams C, Hynes WM. Differences in physician compensation for cardiovascular services by age, sex, and race. The American Journal Of Managed Care 1997, 3: 557-63. PMID: 10169524.Peer-Reviewed Original ResearchConceptsConsecutive patientsCoronary angioplastyCardiovascular servicesPercutaneous transluminal coronary angioplastyPatients 75 yearsTransluminal coronary angioplastyPercutaneous coronary angioplastyPatients 40Patients 65Patient characteristicsPatient groupInsurance statusCardiology practicePhysiciansStress testingAngioplastySignificant differencesPatientsLower ratesSimilar differencesPhysician compensationAgeSexYearsDifferences